Amylyx Just Printed a Phase 3 Win Wall Street Wasn't Pricing

Most people only know GLP-1 drugs as the weight-loss shots that emptied fridge aisles and filled magazine covers. Amylyx Pharmaceuticals (AMLX) just reminded the market that the same hormone system can go too far the other way. On Tuesday, Amylyx said its Phase 3 LUCIDITY trial of avexitide hit the FDA-agreed primary endpoint in post-bariatric hypoglycemia. That is the nasty crash in blood sugar some patients get after Roux-en-Y gastric bypass. The composite rate of Level 2 and Level 3 hypoglycemic events fell 55% versus placebo. The p-value was the kind of number statisticians brag about at dinner. Secondary endpoints cleared too. The stock closed at $35.11. The day before it finished at $21.43. That is not a polite gap. That is the market rewriting the story in one session. ## The problem nobody markets on Super Bowl Sunday Weight-loss surgery helps a lot of people. It also leaves a subset with a cruel aftereffect. After a meal, insulin and gut signals can overshoot. Blood sugar falls hard enough to cause confusion, seizures, or emergency care. Patients learn to fear food. Doctors have limited approved tools that actually target the mechanism. Avexitide is not another appetite-suppressing GLP-1 agonist. It is a GLP-1 receptor antagonist. Plain English: it tries to block the overstimulation that can dump sugar too low after bypass surgery. Amylyx has called it first-in-class. The FDA already handed it Breakthrough Therapy Designation in this setting. LUCIDITY enrolled 78 participants in a randomized, double-blind, placebo-controlled design across U.S. sites. Primary readout ran through week 16. That is a small pivotal trial by big-pharma standards. It is also the right size for a rare, high-burden niche with a clean binary. Hit the endpoint or do not. Amylyx hit it. ## Why the move looks so violent Before the print, AMLX was still trading like a company people half-remembered from the ALS era and half-doubted on the PBH pivot. A stock near the low $20s into a known data window is the market saying "prove it." A close above $35 after a clean primary is the market saying "fine, you proved the science chapter." The commercial tease writes itself. Millions of Americans have had bariatric surgery. Only a slice develop severe PBH. That slice is miserable, visible to specialists, and short on good options. Orphan-style pricing power is how these stories get modeled on the bull whiteboard. Amylyx has talked about a potential 2027 commercial launch if regulators cooperate. Then comes the part retail cheers past and institutions never forget. Same day energy around the win included a large proposed equity raise. Call it what it is: the company may try to fund the next leg while the stock is hot. A Phase 3 win that also opens the dilution spigot is still a win. It is not a free lunch. ## What still has to go right Approval is not automatic because a primary endpoint printed. Regulators will pore over safety, durability, real-world use, and whether the label can be clean enough for specialists to prescribe without a headache. Manufacturing, payer fights, and launch execution can turn a beautiful p-value into a slow slog. Competition and category risk matter too. The obesity and metabolic field moves fast. A drug that sits on the other side of the GLP-1 craze has to keep explaining itself every earnings season. And AMLX remains a small biotech. One asset carrying the narrative means every delay hits twice as hard. Still, do not miss the simple tell. Wall Street can argue about peak sales until the cows come home. It cannot pretend a 55% cut in dangerous lows was "in the price" at $21. ## Bottom Line Amylyx just turned avexitide from a hope slide into a Phase 3 fact pattern in post-bariatric hypoglycemia. The stock's one-day rip prices a lot of that relief already. From here the fight is narrower and meaner: can the company get a clean path to market without giving the whole upside back to new shareholders and to time? The science chapter got a lot harder to ignore on Tuesday. The capital-markets chapter is only getting started.